And let's not forget about Fucsylation which enhances homing and engraftment for the 2nd generation of our MPC's. A combination study is currently underway funded by the NIH and the MD Anderson Cancer Centre.
The modified cells demonstrate enhanced homing properties to tissues that are inflamed.
In Phase 2 studies, over a 3 year period 71% of patients treated with placebo had a HF-MACE event, while none of those treated with MPC-150 did.
Every chance that the combined therapy will demonstrate efficacy over more patients than just those very sick patients.
I would expect that the FDA is aware and interested in the above.
And let's not forget about Fucsylation which enhances homing and...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.015(1.49%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 94.0¢ | $11.76M | 11.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 206912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 37637 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |